BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Salmeterol Xinafoate

A selective ADRENERGIC BETA-2 RECEPTOR agonist that functions as a BRONCHODILATOR when administered by inhalation. It is used to manage the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

227+ PubMed studies analyzed · 53 RCTs · Evidence Score: 53.9

Research Domains

Salmeterol Xinafoate has been studied across 7 research domains including 🫁 Respiratory, 🫘 Kidney, 🔬 Inflammation, 🫁 Liver & Detox, 😴 Sleep. The primary research focus is 🫁 Respiratory with 78% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Salmeterol Xinafoate, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

trequinsin
16 shared targets
Lynestrenol
14 shared targets
o-Phthalaldehyde
13 shared targets
Quinestrol
11 shared targets
Nisoldipine
23 shared targets
Polidocanol
11 shared targets
Fluvoxamine
12 shared targets
Flutamide
15 shared targets
triflupromazine
15 shared targets
Promethazine
15 shared targets
Loading evidence profile...

This evidence profile for Salmeterol Xinafoate is generated deterministically from 227 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.